1. Home
  2. CVEO vs RVMDW Comparison

CVEO vs RVMDW Comparison

Compare CVEO & RVMDW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVEO
  • RVMDW
  • Stock Information
  • Founded
  • CVEO 1977
  • RVMDW N/A
  • Country
  • CVEO United States
  • RVMDW United States
  • Employees
  • CVEO N/A
  • RVMDW 490
  • Industry
  • CVEO Hotels/Resorts
  • RVMDW
  • Sector
  • CVEO Consumer Discretionary
  • RVMDW
  • Exchange
  • CVEO Nasdaq
  • RVMDW Nasdaq
  • Market Cap
  • CVEO N/A
  • RVMDW N/A
  • IPO Year
  • CVEO N/A
  • RVMDW N/A
  • Fundamental
  • Price
  • CVEO $23.72
  • RVMDW $0.17
  • Analyst Decision
  • CVEO Strong Buy
  • RVMDW
  • Analyst Count
  • CVEO 1
  • RVMDW 0
  • Target Price
  • CVEO $32.00
  • RVMDW N/A
  • AVG Volume (30 Days)
  • CVEO 49.3K
  • RVMDW N/A
  • Earning Date
  • CVEO 02-27-2025
  • RVMDW N/A
  • Dividend Yield
  • CVEO 4.22%
  • RVMDW N/A
  • EPS Growth
  • CVEO N/A
  • RVMDW N/A
  • EPS
  • CVEO 1.44
  • RVMDW N/A
  • Revenue
  • CVEO $701,970,000.00
  • RVMDW N/A
  • Revenue This Year
  • CVEO $0.97
  • RVMDW N/A
  • Revenue Next Year
  • CVEO $3.72
  • RVMDW N/A
  • P/E Ratio
  • CVEO $16.42
  • RVMDW N/A
  • Revenue Growth
  • CVEO 1.41
  • RVMDW N/A
  • 52 Week Low
  • CVEO $21.15
  • RVMDW N/A
  • 52 Week High
  • CVEO $28.92
  • RVMDW N/A
  • Technical
  • Relative Strength Index (RSI)
  • CVEO 55.77
  • RVMDW N/A
  • Support Level
  • CVEO $23.50
  • RVMDW N/A
  • Resistance Level
  • CVEO $24.13
  • RVMDW N/A
  • Average True Range (ATR)
  • CVEO 0.46
  • RVMDW 0.00
  • MACD
  • CVEO 0.22
  • RVMDW 0.00
  • Stochastic Oscillator
  • CVEO 81.02
  • RVMDW 0.00

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: